FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
W World Corp. Stock AnalysisComprehensive stock analysis for W World Corp. (WWHC) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisWWHC
WWHC
W World Corp.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
WWHC
Home🔹Stocks🔹W World Corp.

W World Corp.

WWHC•OTC

W World Corp.

WWHC•OTC
Market cap
$80.24M
Sentiment

Your view on WWHC

Mkt Cap
$80.24M
Sentiment
Your view
WWHC
W World Corp.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
WWHC
Company Overview

Overview

What the company does, where it operates, and who runs it.

About W World Corp.

Industry
Shell Companies
Sector
Financial Services
CEO
Eric W. Fangmann
Headquarters
3609 Hammerkop Drive, North Las Vegas, NV, US
Industry
Shell Companies
Sector
Financial Services
CEO
Eric W. Fangmann
Headquarters
3609 Hammerkop Drive, North Las Vegas, NV, US
Description

W World Corp., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat a range of metabolic and nervous system disorders. The company focuses on the disorders of the brain-gut axis, pain/inflammation, and autoimmune, as well as gout disorders. Its lead compounds under clinically development include Levotofisopam, a non-sedating agent for the treatment of Gout; and Dextofisopam, a non-serotonergic agent, which has completed Phase IIa and Phase IIb clinical trials for the treatment of irritable bowel syndrome. The company was founded in 1990 and is headquartered in North Las Vegas, Nevada.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News